{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:11:38Z","timestamp":1730434298652,"version":"3.28.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to investigate the effect of three selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine and sertraline, on the pharmacokinetics and metabolism of perazine in a steady state in rats. Perazine (10 mg kg\u22121, i.p.) was administered twice daily for two weeks, alone or jointly with one of the SSRIs. Concentrations of perazine and its two main metabolites (N-desmethylperazine and 5-sulfoxide) in the plasma and brain were measured 30 min and 6 and 12 h after the last dose of the drugs. Of the investigated SSRIs, fluoxetine and fluvoxamine significantly increased plasma and brain concentrations of perazine (up to 900% and 760% of the control value, respectively), their effect being most pronounced after 30 min and 6 h. Moreover, simultaneous increases in perazine metabolites concentrations and in the perazine\/metabolite concentration ratios were observed. Sertraline elevated plasma and brain concentrations of perazine after 30 min. In-vitro studies with liver microsomes of rats treated chronically with perazine, SSRIs or their combinations showed decreased concentrations of cytochrome P-450 after perazine and a combination of perazine and fluvoxamine (vs control), and increased concentration after a combination of perazine and fluoxetine (vs perazine-treated group). Prolonged treatment with perazine did not significantly change the rate of its own metabolism. Chronic administration of fluoxetine or sertraline, alone or in a combination with perazine, accelerated perazine N-demethylation (vs control or perazine group, respectively). Fluvoxamine had a similar effect. The 5-sulfoxidation of perazine was accelerated by fluvoxamine and sertraline treatment, but the process was inhibited by administration of a combination of perazine and fluoxetine or fluvoxamine (vs control). Kinetic studies using control liver microsomes, in the absence or presence of SSRIs added in-vitro, demonstrated competitive inhibition of both N-demethylation and sulfoxidation by the investigated SSRIs. Sertraline was the most potent inhibitor of perazine N-demethylation but the weakest inhibitor of sulfoxidation. Results of in-vivo and in-vitro studies indicate that the observed interaction between perazine and SSRIs mainly involves competition for an active site of perazine N-demethylase and sulfoxidase. Moreover, increases in the concentrations of both perazine and metabolites measured, produced by the investigated drug combinations in-vivo, suggest simultaneous inhibition of another, yet to be investigated, metabolic pathway of perazine (e.g. aromatic hydroxylation).<\/jats:p>","DOI":"10.1211\/0022357011775749","type":"journal-article","created":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T23:43:52Z","timestamp":1058571832000},"page":"449-461","source":"Crossref","is-referenced-by-count":8,"title":["The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat"],"prefix":"10.1093","volume":"53","author":[{"given":"W\u0142adys\u0142awa A","family":"Daniel","sequence":"first","affiliation":[{"name":"Polish Academy of Sciences, Institute of Pharmacology , Sm\u0229tna 12, 31-343 Krak\u00f3w,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Syrek","sequence":"additional","affiliation":[{"name":"Polish Academy of Sciences, Institute of Pharmacology , Sm\u0229tna 12, 31-343 Krak\u00f3w,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Haduch","sequence":"additional","affiliation":[{"name":"Polish Academy of Sciences, Institute of Pharmacology , Sm\u0229tna 12, 31-343 Krak\u00f3w,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"W\u00f3jcikowski","sequence":"additional","affiliation":[{"name":"Polish Academy of Sciences, Institute of Pharmacology , Sm\u0229tna 12, 31-343 Krak\u00f3w,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,4,1]]},"reference":[{"key":"2024103110053977400_cit1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/S1043-6618(97)90144-5","article-title":"Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications","volume":"35","author":"Avenoso","year":"1997","journal-title":"Pharmacol. Res."},{"key":"2024103110053977400_cit2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses","volume":"45","author":"Baldessarini","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"2024103110053977400_cit3","first-page":"239","article-title":"Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction","volume":"51","author":"Bergstrom","year":"1992","journal-title":"Clin. Pharmacol."},{"key":"2024103110053977400_cit4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0006-2952(69)90048-3","article-title":"Urinary metabolites of 10-[3\u2032-(4\u201c-methylpiperazinyl)-propyl]-phenothiazine (Perazine) in psychiatric patients - I. Isolation, identification and determination of metabolites","volume":"18","author":"Breyer","year":"1969","journal-title":"Biochem. Pharmacol."},{"key":"2024103110053977400_cit5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/0006-2952(72)90366-8","article-title":"Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats","volume":"21","author":"Breyer","year":"1972","journal-title":"Biochem. Pharmacol."},{"key":"2024103110053977400_cit6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-2007-1019491","article-title":"Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data","volume":"16","author":"Breyer-Pfaff","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"2024103110053977400_cit7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/clpt.1991.77","article-title":"Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine","volume":"49","author":"Br\u00f8sen","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110053977400_cit8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(93)90272-X","article-title":"Fluvoxamine is a potent inhibitor of cytochrome P4501A2","volume":"45","author":"Br\u00f8sen","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"2024103110053977400_cit9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF02244004","article-title":"Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat","volume":"100","author":"Caccia","year":"1990","journal-title":"Psychopharmacology"},{"key":"2024103110053977400_cit10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","article-title":"The effect of selective re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes","volume":"34","author":"Crewe","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2024103110053977400_cit11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","article-title":"Disposition of perphenazine is related to the polymorphic hydroxylation in human beings","volume":"46","author":"Dahl-Puustinen","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110053977400_cit12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0924-977X(99)00034-6","article-title":"Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants","volume":"9","author":"Daniel","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2024103110053977400_cit13","first-page":"431","article-title":"Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine","volume":"50","author":"Daniel","year":"1998","journal-title":"Pol. J. Pharmacol."},{"key":"2024103110053977400_cit14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0940-2993(99)80012-8","article-title":"The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies","volume":"51","author":"Daniel","year":"1999","journal-title":"Exp. Toxic. Pathol."},{"key":"2024103110053977400_cit15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0924-977X(99)00006-1","article-title":"The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat","volume":"9","author":"Daniel","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2024103110053977400_cit16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0278-5846(94)00110-4","article-title":"Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo","volume":"19","author":"Fuller","year":"1995","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiat."},{"key":"2024103110053977400_cit17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF02246213","article-title":"A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia","volume":"117","author":"Goff","year":"1995","journal-title":"Psychopharmacology"},{"key":"2024103110053977400_cit18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(90)90006-N","article-title":"Molecular genetics of the P-450 Superfamily","volume":"45","author":"Gonzalez","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"2024103110053977400_cit19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003088-199427040-00005","article-title":"Pharmacokinetic optimisation of therapy with newer antidepressants","volume":"27","author":"Goodnick","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"2024103110053977400_cit20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002280050163","article-title":"Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine","volume":"51","author":"Jeppesen","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024103110053977400_cit21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00404219","article-title":"Urinary metabolites of 10-[3\u2032-(4\u201c-methylpiperazinyl)-propyl]-phenothiazine (Perazine) in psychiatric patients - II. Individual metabolite patterns and their changes in the course of treatment","volume":"14","author":"Kanig","year":"1969","journal-title":"Psychopharmacologia (Berl.)"},{"key":"2024103110053977400_cit22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF02244982","article-title":"Pharmacologic treatment of schizoaffective disorder","volume":"114","author":"Keck","year":"1994","journal-title":"Psychopharmacology"},{"issue":"Suppl. 5","key":"2024103110053977400_cit23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2125.1995.tb05793.x","article-title":"The effect of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4\u2032-hydroxylase activity in human liver microsomes","volume":"40","author":"Kobayashi","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2024103110053977400_cit24","first-page":"763","article-title":"Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl.","key":"2024103110053977400_cit25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0269881195009002011","article-title":"The SSRIs: advantages, disadvantages and differences","volume":"9","author":"Lane","year":"1995","journal-title":"J. Psychopharmacol."},{"key":"2024103110053977400_cit26","first-page":"271","article-title":"Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human 2D6","volume":"5","author":"Laurenzana","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"2024103110053977400_cit27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"2024103110053977400_cit28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01244819","article-title":"Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations","volume":"88","author":"Maj","year":"1992","journal-title":"J. Neural Transm."},{"key":"2024103110053977400_cit29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0924-977X(93)90259-O","article-title":"Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists","volume":"3","author":"Maj","year":"1993","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2024103110053977400_cit30","first-page":"431","article-title":"The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan","volume":"30","author":"Maj","year":"1978","journal-title":"Pol. J. Pharmacol."},{"key":"2024103110053977400_cit31","first-page":"305","article-title":"Some central effects of repeated treatment with fluvoxamine","volume":"41","author":"Maj","year":"1989","journal-title":"Pol. J. Pharmacol."},{"key":"2024103110053977400_cit32","first-page":"254","article-title":"Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia","volume":"19","author":"Midha","year":"1994","journal-title":"J. Psychiatr. Neurosci."},{"key":"2024103110053977400_cit33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02247719","article-title":"Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotyline","volume":"109","author":"Muscat","year":"1992","journal-title":"Psychopharmacology"},{"issue":"Suppl. 9","key":"2024103110053977400_cit34","first-page":"42","article-title":"Combined treatment strategies in psychiatry","volume":"54","author":"Nelson","year":"1993","journal-title":"J. Clin. Psychiatry"},{"key":"2024103110053977400_cit35","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature","volume":"239","author":"Omura","year":"1964","journal-title":"J. Biol. Chem."},{"key":"2024103110053977400_cit36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/oxfordjournals.jbchem.a129248","article-title":"A new method for simultaneous purification of cytochrome b and NADPH-cytochrome reductase from rat liver microsomes","volume":"67","author":"Omura","year":"1970","journal-title":"J. Biochem. (Tokyo)"},{"key":"2024103110053977400_cit37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0009-9236(97)90037-0","article-title":"Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo","volume":"62","author":"\u00d6zdemir","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 1","key":"2024103110053977400_cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin. Pharmacokin."},{"key":"2024103110053977400_cit39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-1014589","article-title":"Monitoring of serum bioactivity levels of perazine and its metabolites by radioreceptor assay","volume":"22","author":"Rao","year":"1989","journal-title":"Pharmacopsychiatry"},{"key":"2024103110053977400_cit40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/0006-3223(92)90279-9","article-title":"Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add on double blind, placebo-controlled study","volume":"31","author":"Silver","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"2024103110053977400_cit41","first-page":"314","article-title":"Hydroxylation of desmethylimipramine: dependence on debrisoquin hydroxylation phenotype","volume":"41","author":"Spina","year":"1987","journal-title":"Clin. Pharmacol."},{"key":"2024103110053977400_cit42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-199733060-00004","article-title":"Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence","volume":"33","author":"Sproule","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"2024103110053977400_cit43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/clpt.1988.76","article-title":"Inhibition of desipramine 2-hydroxylation by quinidine and quinine","volume":"43","author":"Steiner","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110053977400_cit44","first-page":"542","article-title":"Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog","volume":"17","author":"Tremaine","year":"1989","journal-title":"Drug Metab. Dispos."},{"key":"2024103110053977400_cit45","first-page":"551","article-title":"Pharmacokinetics of neuroleptics","volume":"27","author":"Vergese","year":"1991","journal-title":"Psychopharmacol. Bull."},{"key":"2024103110053977400_cit46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004714-199504000-00008","article-title":"Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor anti-depressants","volume":"15","author":"Von Moltke","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"2024103110053977400_cit47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002130050456","article-title":"Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation","volume":"134","author":"Willner","year":"1997","journal-title":"Psychopharmacology"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357011775749","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/53\/4\/449\/60263783\/0022357011775749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/53\/4\/449\/60263783\/0022357011775749.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:45:12Z","timestamp":1730371512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/53\/4\/449\/6149833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,4,1]]},"published-print":{"date-parts":[[2001,4,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357011775749","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2001,4]]},"published":{"date-parts":[[2001,4,1]]}}}